Journal Of Oncology Practice Podcast
Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:13:38
- Mas informaciones
Informações:
Sinopsis
Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.
